aap Implantate AG

  • WKN: 506660
  • ISIN: DE0005066609
  • Land: Deutschland

Nachricht vom 21.04.2017 | 10:26

aap Implantate AG: aap concludes distribution agreement for LOQTEQ(R) Radius System with leading US medical technology company

DGAP-News: aap Implantate AG / Key word(s): Alliance/Agreement

21.04.2017 / 10:26
The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("aap") announces the conclusion of a distribution agreement for its LOQTEQ(R) Radius System with a worldwide leading US medical technology company.

According to the agreement, the LOQTEQ(R) Radius System is non-exclusively distributed in the entire territory of the United States. aap relies on a hybrid distribution strategy in North America. Distribution takes place both via distribution agents and through partnerships with global orthopaedic and medical technology companies.

The conclusion of the agreement represents further important progress in the aimed distribution focus on established markets such as North America, the DACH region and further European countries. The partnership with this customer will additionally support the dynamic development in North America and thus contribute to the further planned sales growth in this strategic core market.

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de
 



21.04.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

News im Fokus

IRprint: Nachhaltiger Eindruck durch einen professionellen Ausdruck

Das Team von IRprint bietet für geschäftliche Dokumente einen persönlichen Service mit langjähriger Finanzmarktexpertise – angefangen bei der Erstellung von Textinhalten bis hin zum professionellen Druck sowohl im Digital- als auch Offsetdruckverfahren.

Nutzen Sie unser Knowhow in der Kapitalmarktkommunikation und unsere exklusive Kooperation mit CEWE, Europas Marktführer im Bereich Fotoservice mit herausragender Expertise im kommerziellen Online-Druck. So gelingt Ihnen sowohl inhaltlich als auch optisch ein glänzender Auftritt.

GBC im Fokus

SYGNIS AG will mit Innova-Übernahme Synergieeffekte heben

Die SYGNIS AG plant, mit den aktuellen Kapitalerhöhungen (bis zu 10 Mio. €) den Erwerb der Innova Biosciences Ltd. zu finanzieren, eines Spezialisten aus dem Bereich der Proteinmarkierung. Mit dem Erwerb des profitablen Unternehmens sollen Synergieeffekte gehoben, der Workflow erweitert und darüber hinaus die operativen Kennzahlen verbessert werden. Sowohl im Peer-Group-Vergleich als auch innerhalb eines DCF-Bewertungsmodells stufen wir den Kaufpreis als sehr attraktiv ein.

News im Fokus

Linde AG: Linde AG bestätigt grundsätzliche Einigung mit Praxair, Inc. über das Business Combination Agreement zu dem Zusammenschluss unter Gleichen vorbehaltlich Gremienzustimmung beider Seiten

24. Mai 2017, 16:20

Aktueller Webcast

Douglas Holding AG

6M Interim Financial Results

24. Mai 2017

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

26. Mai 2017